Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).

Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12

Immune microenvironments in solid tumors: new targets for therapy. Genes Dev (2011) 2.08

Therapeutic cancer vaccines: are we there yet? Immunol Rev (2011) 1.86

Cancer vaccines and carbohydrate epitopes. Vaccine (2011) 1.40

Bacteria and cancer: cause, coincidence or cure? A review. J Transl Med (2006) 1.38

Immunotherapy for metastatic solid cancers. Adv Surg (2011) 1.16

Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer. Cancer Res (2012) 1.08

Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer. Trends Mol Med (2007) 1.08

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? J Thorac Oncol (2016) 1.03

Lung cancer: Biology and treatment options. Biochim Biophys Acta (2015) 1.02

Immunological monitoring of anticancer vaccines in clinical trials. Oncoimmunology (2013) 0.95

Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res (2015) 0.94

Clinical evaluation of therapeutic cancer vaccines. Hum Vaccin Immunother (2013) 0.93

Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data. Front Oncol (2012) 0.93

Targeted therapies in small cell lung cancer. Oncol Lett (2012) 0.92

Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins. Front Oncol (2012) 0.92

Targeted therapies in small cell lung cancer: a review. Ther Adv Med Oncol (2010) 0.91

The role of the immune response in merkel cell carcinoma. Cancers (Basel) (2013) 0.91

The development of targeted therapy in small cell lung cancer. J Thorac Dis (2013) 0.90

Immunotherapy for lung cancer: advances and prospects. Am J Clin Exp Immunol (2016) 0.89

Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis. Sci Rep (2015) 0.89

Challenges in the development of an autologous heat shock protein based anti-tumor vaccine. Hum Vaccin Immunother (2012) 0.88

Current status of immunotherapy for the treatment of lung cancer. J Thorac Dis (2010) 0.88

Anti-ganglioside anti-idiotypic vaccination: more than molecular mimicry. Front Oncol (2012) 0.87

Immunotherapy prospects in the treatment of lung cancer and mesothelioma. Transl Lung Cancer Res (2014) 0.85

Novel therapies in small cell lung cancer. Transl Lung Cancer Res (2015) 0.84

Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy. Clin Exp Immunol (2012) 0.84

Immunotherapy in lung cancer. Transl Lung Cancer Res (2014) 0.82

Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci. Cancer Immunol Immunother (2011) 0.82

Glycosylation of glycolipids in cancer: basis for development of novel therapeutic approaches. Front Oncol (2013) 0.80

Cancer stem cells in small cell lung cancer. Transl Lung Cancer Res (2016) 0.80

Immunotherapy in lung cancer. Transl Lung Cancer Res (2014) 0.80

Cancer stem cells and immunoresistance: clinical implications and solutions. Transl Lung Cancer Res (2015) 0.79

Cellular and molecular biology of small cell lung cancer: an overview. Transl Lung Cancer Res (2016) 0.79

Small cell lung cancer (SCLC): no treatment advances in recent years. Transl Lung Cancer Res (2016) 0.79

The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer. Oncologist (2016) 0.78

Targeted drugs in small-cell lung cancer. Transl Lung Cancer Res (2016) 0.77

Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting. Ann Transl Med (2016) 0.77

Novel therapeutic approaches for small cell lung cancer: the future has arrived. Curr Probl Cancer (2012) 0.77

Immunotherapy for lung cancers. J Biomed Biotechnol (2011) 0.76

Immunotherapy treatments for small-cell lung cancer: past, present and future. Lung Cancer Manag (2015) 0.75

Respiratory Homeostasis and Exploitation of the Immune System for Lung Cancer Vaccines. US Oncol (2009) 0.75

Research progress in the treatment of small cell lung cancer. J Cancer (2017) 0.75

Therapeutic vaccines in non-small cell lung cancer. Immunotargets Ther (2013) 0.75

Chemotherapy for small cell lung cancer: a comprehensive review. Oncol Rev (2012) 0.75

Novel compounds in the treatment of lung cancer: current and developing therapeutic agents. J Exp Pharmacol (2011) 0.75

The Humanistic Burden of Small Cell Lung Cancer (SCLC): A Systematic Review of Health-Related Quality of Life (HRQoL) Literature. Front Pharmacol (2017) 0.75

Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54

Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med (2012) 11.14

First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med (2014) 10.91

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39

Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12

Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 9.94

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med (2010) 8.10

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (2012) 8.00

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol (2009) 7.80

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med (2015) 7.11

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A (2010) 6.54

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol (2003) 5.84

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71

Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst (2007) 4.40

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst (2007) 4.07

Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol (2004) 4.06

Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol (2007) 3.88

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet (2010) 3.78

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71

Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol (2002) 3.69

When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst (2007) 3.60

KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03

Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol (2002) 2.98

Evolutionary dynamics of cancer in response to targeted combination therapy. Elife (2013) 2.76

Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer (2010) 2.73

Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol (2009) 2.64

Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. J Clin Oncol (2003) 2.62

Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst (2011) 2.56

Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw (2013) 2.56

Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol (2009) 2.50

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol (2011) 2.48

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45

Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst (2003) 2.44

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol (2013) 2.41

Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. J Clin Oncol (2013) 2.32

Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res (2010) 2.31

Cross-presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med (2003) 2.30

Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol (2005) 2.26

Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med (2012) 2.19

Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. J Clin Oncol (2002) 2.18

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol (2005) 2.15

First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol (2010) 2.05

BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet (2004) 2.05

An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer (2008) 1.95

Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res (2008) 1.94

Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol (2008) 1.92

An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer (2010) 1.84

Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol (2010) 1.83

Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer (2006) 1.75

Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol (2002) 1.72

Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol (2007) 1.72

Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol (2009) 1.66

Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol (2013) 1.62

The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer (2011) 1.62

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res (2014) 1.59

Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial. Eur J Cancer (2010) 1.57

Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol (2011) 1.55

Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res (2013) 1.55

Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res (2014) 1.55

Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J Clin Oncol (2002) 1.54

Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. J Clin Oncol (2006) 1.52

Squamoproliferative lesions arising in the setting of BRAF inhibition. Am J Dermatopathol (2012) 1.51

A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J (2014) 1.51

Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Clin Transl Oncol (2012) 1.48

Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial. Lancet Oncol (2005) 1.48

Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy. J Clin Oncol (2014) 1.47

Variates of survival in metastatic uveal melanoma. J Clin Oncol (2005) 1.45

Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer (2006) 1.43

Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer (2011) 1.41

Audit of patients with mesothelioma treated with pemetrexed in a single institution in Western Australia. Asia Pac J Clin Oncol (2010) 1.40

Helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b. Oncologist (2005) 1.38

Clinical significance of BRAF mutations in metastatic melanoma. J Transl Med (2004) 1.38

Therapeutic implications of the emerging molecular biology of uveal melanoma. Clin Cancer Res (2011) 1.34

Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clin Cancer Res (2013) 1.34

Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study. Lung Cancer (2010) 1.34

Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann Surg Oncol (2013) 1.32

Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res (2009) 1.32

Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res (2004) 1.32

Projected future climate change and Baltic Sea ecosystem management. Ambio (2015) 1.32

Measurement of lung tumor volumes using three-dimensional computer planning software. Int J Radiat Oncol Biol Phys (2002) 1.25

Vemurafenib sensitivity skin reaction after ipilimumab. N Engl J Med (2012) 1.25

Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. Cancer Discov (2014) 1.25

Personalizing therapy with targeted agents in non-small cell lung cancer. Oncotarget (2011) 1.24

Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study. Radiother Oncol (2010) 1.23

Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol Ther (2008) 1.22